Pelvic Cancer Registry for Online Adapted Radiotherapy

This prospective registry-based trial will include patients with pelvic or thoracic tumors with an indication for radiotherapy treated with oART or IGRT. For the primary endpoint and the secondary clinical endpoints, the trial will compare oART versus IGRT, for technical endpoints the trial will compare the real oART scenario with two virtual (hypothetical) control scenarios. Primary endpoint: * 10% reduction in the rate of acute radiotherapy related toxicity (≥ CTCAE II°, v5.0) using oART Secondary endpoints: * Clinical endpoints: Tumor control, late toxicities compared to conventional irradiated patients, quality of life and patient-reported outcomes * Technical endpoints: Target volume, target coverage, dose to organs at risk, anatomical variability score

NCT Number	NCT06185062
Lead Sponsor	University Medical Center Goettingen
Conditions	Pelvic Tumor, Thoracic Tumor
Enrollment	846 participants
Start Date	2024-01-01
Primary Completion	2029-09 (estimated)
Study Completion	2030-04 (estimated)
Updated on ClinicalTrials.gov	2024-02-08